Evidence map›Paper›PMID 30736370›Full record

ArticleMarine drugs2019

New Acyclic Cytotoxic Jasplakinolide Derivative from the Marine Sponge

Sherif S Ebada, Werner E G Müller, Wenhan Lin, Peter Proksch

Abstract read
In one paragraph

Article in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Jaspamide/Jasplakinolide Is Synthesized byJournal of natural products · 2025
    Article
  4. Naturally Occurring Organohalogen Compounds-A Comprehensive Review.Progress in the chemistry of organic natural products · 2023
    Review
  5. Structure-Activity Relationship of Cytotoxic Natural Products from Indonesian Marine Sponges.Revista brasileira de farmacognosia : orgao oficial da Sociedade Brasileira de Farmacognosia · 2022
    Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sherif S EbadaInstitute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University, Universitaetsstrasse 1, D-40225 Duesseldorf, Germany. sherif_elsayed@pharma.asu.edu.eg.ORCID 0000-0002-2753-0031
Werner E G MüllerInstitute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz, 55128 Mainz, Germany. wmueller@uni-mainz.de.
Wenhan LinState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100083, China. whlin@bjmu.edu.cn.ORCID 0000-0002-4978-4083
Peter ProkschInstitute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University, Universitaetsstrasse 1, D-40225 Duesseldorf, Germany. ss_ebada@mutah.edu.jo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new acylic jasplakinolide congener (

Indexed as

AnimalsCarbon-13 Magnetic Resonance SpectroscopyCell Line, TumorCell ProliferationDepsipeptidesLeukemia L5178MicePoriferaProton Magnetic Resonance SpectroscopyDepsipeptidesjasplakinolidecytotoxic activityJaspis splendensjasplakinolide Z5jasplakinolide Z6

Identifiers

PMID30736370
PMCPMC6409940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.